Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28961)	6/24/1999 5:00:00 PM
From: J Stone	Read Replies (1) \| Respond to of 32384

Not sure what to make of the tight trading range given the volume. If the trial stats on Targretin are a slam dunk for FDA approval (I'll leave that determination to others), then investor interest should gradually gain strength (absent a big ABC announcement) up to when approval is given assuming the next two earnings reports show reduced losses with increased sales for ONTAK and Panretin gel. Conversely, uncertainty about Targretin's approval will at best cause the price to languish. Since the price didn't move much, any guesses as to whether management has other stock boosting news prior to the Seragen pay date?